Health Economics›Bladder cancer›Locally advanced or metastatic disease, first-line, platinum-eligible

Locally advanced or metastatic disease, first-line, platinum-eligible

Bladder cancer · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	15.1 mo	—	—	1
Carboplatin and Gemcitabine (GCb) and Pembrolizumab Variant #01	—	R 85 650	21d	8.3 mo	17.0 mo	13	R 1 113 454 PFS proxy	2
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 180	21d	8.3 mo	17.0 mo	13	R 1 107 338 PFS proxy	2
Carboplatin and Gemcitabine (GCb) and Atezolizumab Variant #01	—	R 35 020	21d	—	16.0 mo	—	—	1
Cisplatin and Gemcitabine (GC) and Atezolizumab Variant #01	—	R 34 447	21d	—	16.0 mo	—	—	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	15.7 mo	—	—	1
Cisplatin and Gemcitabine (GC) and Bevacizumab Variant #01	—	R 18 265	21d	—	14.5 mo	—	—	1
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	6.4 mo	14.3 mo	4	R 61 352 PFS proxy	13
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	—	13.8 mo	—	—	—
PGC Variant #01	—	R 3 886	21d	—	15.8 mo	—	—	1
MVAC, dose-dense Variant #01	—	R 3 841	14d	—	17.1 mo	—	—	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	6.3 mo	15.9 mo	10	R 36 631 PFS proxy	9
MVAC Variant #01	—	R 1 082	28d	—	15.1 mo	—	—	3
CISCA Variant #02	—	R 678	21d	—	—	—	—	—
Cisplatin monotherapy Variant #16	—	R 650	28d	~2.1 mo	~8.7 mo	~3	~R 1 950 PFS proxy · indirect	8
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	—	~7.8 mo	—	—	—

16 of 16 regimens shown